HRP20230616T1 - Disperzivni pripravci - Google Patents

Disperzivni pripravci Download PDF

Info

Publication number: HRP20230616T1
Authority: HR; Croatia
Prior art keywords: intragranular; preparation; tablet; fraction; extragranular
Prior art date: 2015-01-27

Application number

HRP20230616TT

Other languages

English (en)

Croatian (hr)

Inventor

Manish Kumar Gupta

Shripad Wasudeo Marathe

Kaustubh Ramesh Tambwekar

Shreedevi Velayudhan Nair

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-27

Filing date

2016-01-26

Publication date

2023-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55229712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20230616(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-01-26 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2023-09-29 Publication of HRP20230616T1 publication Critical patent/HRP20230616T1/hr

Links

239000000203 mixture Substances 0.000 title 1
238000002360 preparation method Methods 0.000 claims 22
239000000945 filler Substances 0.000 claims 18
239000011230 binding agent Substances 0.000 claims 12
239000000546 pharmaceutical excipient Substances 0.000 claims 10
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 8
229960001137 bedaquiline fumarate Drugs 0.000 claims 8
ZLVSPMRFRHMMOY-WWCCMVHESA-N bedaquiline fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 ZLVSPMRFRHMMOY-WWCCMVHESA-N 0.000 claims 8
229940075614 colloidal silicon dioxide Drugs 0.000 claims 8
229960000913 crospovidone Drugs 0.000 claims 8
239000007884 disintegrant Substances 0.000 claims 8
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 8
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 8
239000000126 substance Substances 0.000 claims 8
239000000314 lubricant Substances 0.000 claims 7
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 6
239000004480 active ingredient Substances 0.000 claims 6
229920000168 Microcrystalline cellulose Polymers 0.000 claims 5
239000003795 chemical substances by application Substances 0.000 claims 5
235000019813 microcrystalline cellulose Nutrition 0.000 claims 5
239000008108 microcrystalline cellulose Substances 0.000 claims 5
229940016286 microcrystalline cellulose Drugs 0.000 claims 5
201000008827 tuberculosis Diseases 0.000 claims 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
229920001213 Polysorbate 20 Polymers 0.000 claims 4
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
229960003943 hypromellose Drugs 0.000 claims 4
229920000642 polymer Polymers 0.000 claims 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 4
229940068977 polysorbate 20 Drugs 0.000 claims 4
229940045902 sodium stearyl fumarate Drugs 0.000 claims 4
239000002904 solvent Substances 0.000 claims 4
239000004094 surface-active agent Substances 0.000 claims 4
239000000080 wetting agent Substances 0.000 claims 4
239000003814 drug Substances 0.000 claims 2
239000004615 ingredient Substances 0.000 claims 2
238000000034 method Methods 0.000 claims 2
229940124597 therapeutic agent Drugs 0.000 claims 2
229920002472 Starch Polymers 0.000 claims 1
239000008213 purified water Substances 0.000 claims 1
239000008107 starch Substances 0.000 claims 1
235000019698 starch Nutrition 0.000 claims 1
239000007916 tablet composition Substances 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cosmetics (AREA)
Lubricants (AREA)

HRP20230616TT 2015-01-27 2016-01-26 Disperzivni pripravci HRP20230616T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN264MU2015		2015-01-27
EP16701516.3A EP3250182B1 (fr)	2015-01-27	2016-01-26	Compositions dispersibles
PCT/EP2016/051545 WO2016120258A1 (fr)	2015-01-27	2016-01-26	Compositions dispersibles

Publications (1)

Publication Number	Publication Date
HRP20230616T1 true HRP20230616T1 (hr)	2023-09-29

Family

ID=55229712

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20230616TT HRP20230616T1 (hr)	2015-01-27	2016-01-26	Disperzivni pripravci

Country Status (29)

Country	Link
US (2)	US20180000810A1 (fr)
EP (1)	EP3250182B1 (fr)
JP (3)	JP7291458B2 (fr)
KR (1)	KR102631986B1 (fr)
CN (2)	CN114129526A (fr)
AU (2)	AU2016212116B2 (fr)
CY (1)	CY1126107T1 (fr)
DK (1)	DK3250182T3 (fr)
EA (1)	EA201791701A1 (fr)
ES (1)	ES2948805T3 (fr)
FI (1)	FI3250182T3 (fr)
HK (1)	HK1243644A1 (fr)
HR (1)	HRP20230616T1 (fr)
HU (1)	HUE062481T2 (fr)
IL (2)	IL310920A (fr)
LT (1)	LT3250182T (fr)
MA (1)	MA41411B1 (fr)
MD (1)	MD3250182T2 (fr)
MX (1)	MX391192B (fr)
PE (1)	PE20171319A1 (fr)
PH (1)	PH12017501331B1 (fr)
PL (1)	PL3250182T3 (fr)
PT (1)	PT3250182T (fr)
RS (1)	RS64308B1 (fr)
SG (1)	SG11201705944TA (fr)
SI (1)	SI3250182T1 (fr)
SM (1)	SMT202300188T1 (fr)
UA (1)	UA126891C2 (fr)
WO (1)	WO2016120258A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2937365C (fr)	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
SI3943070T1 (sl) *	2017-07-14	2024-03-29	Janssen Pharmaceutica Nv,	Dolgo delujoče formulacije bedakilina
CN112243383A (zh) *	2018-04-05	2021-01-19	希普拉有限公司	药物制剂
US11291654B2 (en) *	2018-09-13	2022-04-05	Syneurx International (Taiwan) Corp.	Formulations of cycloserine compounds and applications thereof
US20220023282A1 (en) *	2018-12-13	2022-01-27	Mannkind Corporation	Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
WO2020144197A1 (fr) *	2019-01-09	2020-07-16	Janssen Pharmaceutica Nv	Combinaison dans le traitement de maladies mycobactériennes non tuberculeuses
WO2021257461A1 (fr) *	2020-06-15	2021-12-23	Mylan Laboratories Limited	Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne
EP4164645A4 (fr) *	2020-06-15	2024-07-10	The Global Alliance for TB Drug Development, Inc.	Composition antibactérienne combinée et procédé de thérapie antibactérienne
CN111888477B (zh) *	2020-09-15	2023-03-07	北京福元医药股份有限公司	一种贝达喹啉药物制剂
KR20230107275A (ko) *	2020-11-12	2023-07-14	얀센 파마슈티카 엔.브이.	비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
KR102478006B1 (ko)	2020-12-03	2022-12-15	정승찬	자동차 긴급 제동장치
GB202100470D0 (en) *	2021-01-14	2021-03-03	Summit Oxford Ltd	Solid tablet dosage for of ridinilazole
US11793808B2 (en)	2021-02-22	2023-10-24	Mannkind Corp.	Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
GB202211231D0 (en)	2022-08-02	2022-09-14	Glaxosmithkline Ip No 2 Ltd	Novel formulation
CN120731072A (zh) *	2022-12-17	2025-09-30	维亚治疗有限责任公司	用于治疗儿科结核病的氯法齐明迷你片剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE463482T1 (de)	2002-07-25	2010-04-15	Janssen Pharmaceutica Nv	Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
PL1753427T3 (pl) *	2004-05-28	2008-09-30	Janssen Pharmaceutica Nv	Zastosowanie podstawionych pochodnych chinoliny do leczenia chorób wywoływanych przez prątki lekooporne
EE05394B1 (et)	2004-12-24	2011-04-15	Janssen Pharmaceutica N.V.	Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
SI1888604T1 (sl) *	2005-05-25	2012-08-31	Janssen Pharmaceutica Nv	Postopek priprave (alfa s, beta r)-6-bromo-alfa-(2-(dimetilamino) etil)2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
CA2528849C (fr) *	2005-06-08	2014-01-14	Janssen Pharmaceutica N.V.	Derives de quinoleine utilises comme agents antibacteriens
PE20080422A1 (es) *	2006-08-10	2008-04-28	Cipla Ltd	Composicion solida antirretroviral de administracion oral
UA97813C2 (uk)	2006-12-05	2012-03-26	Янссен Фармацевтика Н.В.	Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) *	2006-12-06	2018-09-16	Janssen Pharmaceutica Nv	مشتقات الكوينولين المضادة للجراثيم
US20110159084A1 (en) *	2008-04-02	2011-06-30	Dr. Reddy's Laboratories Ltd.	Raloxifene pharmaceutical formulations
WO2010026526A1 (fr)	2008-09-03	2010-03-11	Pfizer Inc.	Thérapie combinée pour la tuberculose
US20120207838A1 (en) *	2011-02-10	2012-08-16	Perricone Nicholas V	Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
WO2013153162A1 (fr) *	2012-04-11	2013-10-17	Sandoz Ag	Polymorphe de chlorhydrate de rilpivirine
US20140075692A1 (en) *	2012-09-18	2014-03-20	Unger Marketing International, Llc.	Multiuse cleaning tool handle
AU2013347264B2 (en) *	2012-11-19	2016-10-27	Afyx Therapeutics A/S	Dispersible tablet

2016
- 2016-01-26 IL IL310920A patent/IL310920A/en unknown
- 2016-01-26 MX MX2017009681A patent/MX391192B/es unknown
- 2016-01-26 PL PL16701516.3T patent/PL3250182T3/pl unknown
- 2016-01-26 US US15/545,524 patent/US20180000810A1/en not_active Abandoned
- 2016-01-26 PE PE2017001255A patent/PE20171319A1/es unknown
- 2016-01-26 DK DK16701516.3T patent/DK3250182T3/da active
- 2016-01-26 SM SM20230188T patent/SMT202300188T1/it unknown
- 2016-01-26 HU HUE16701516A patent/HUE062481T2/hu unknown
- 2016-01-26 PT PT167015163T patent/PT3250182T/pt unknown
- 2016-01-26 HR HRP20230616TT patent/HRP20230616T1/hr unknown
- 2016-01-26 RS RS20230495A patent/RS64308B1/sr unknown
- 2016-01-26 CN CN202111218462.7A patent/CN114129526A/zh active Pending
- 2016-01-26 PH PH1/2017/501331A patent/PH12017501331B1/en unknown
- 2016-01-26 HK HK18103261.6A patent/HK1243644A1/zh unknown
- 2016-01-26 SI SI201631721T patent/SI3250182T1/sl unknown
- 2016-01-26 LT LTEPPCT/EP2016/051545T patent/LT3250182T/lt unknown
- 2016-01-26 SG SG11201705944TA patent/SG11201705944TA/en unknown
- 2016-01-26 EP EP16701516.3A patent/EP3250182B1/fr active Active
- 2016-01-26 UA UAA201708632A patent/UA126891C2/uk unknown
- 2016-01-26 ES ES16701516T patent/ES2948805T3/es active Active
- 2016-01-26 MA MA41411A patent/MA41411B1/fr unknown
- 2016-01-26 WO PCT/EP2016/051545 patent/WO2016120258A1/fr not_active Ceased
- 2016-01-26 MD MDE20170303T patent/MD3250182T2/ro unknown
- 2016-01-26 CN CN201680007314.1A patent/CN107205945A/zh active Pending
- 2016-01-26 KR KR1020177023308A patent/KR102631986B1/ko active Active
- 2016-01-26 IL IL253626A patent/IL253626B2/en unknown
- 2016-01-26 AU AU2016212116A patent/AU2016212116B2/en active Active
- 2016-01-26 EA EA201791701A patent/EA201791701A1/ru unknown
- 2016-01-26 JP JP2017557493A patent/JP7291458B2/ja active Active
- 2016-01-26 FI FIEP16701516.3T patent/FI3250182T3/fi active
2021
- 2021-02-12 JP JP2021020595A patent/JP2021098706A/ja active Pending
- 2021-06-21 AU AU2021204135A patent/AU2021204135B2/en active Active
2022
- 2022-02-03 US US17/592,097 patent/US20220331307A1/en not_active Abandoned
- 2022-08-22 JP JP2022131578A patent/JP2022176982A/ja not_active Withdrawn
2023
- 2023-07-07 CY CY20231100319T patent/CY1126107T1/el unknown

Also Published As

Publication number	Publication date
CA2973301A1 (fr)	2016-08-04
AU2021204135A1 (en)	2021-07-15
FI3250182T3 (fi)	2023-06-28
PT3250182T (pt)	2023-07-07
SG11201705944TA (en)	2017-08-30
MA41411B1 (fr)	2023-07-31
HUE062481T2 (hu)	2023-11-28
PL3250182T3 (pl)	2023-07-31
SI3250182T1 (sl)	2023-08-31
AU2016212116B2 (en)	2021-07-15
MX391192B (es)	2025-03-21
EA201791701A1 (ru)	2017-11-30
CN114129526A (zh)	2022-03-04
JP7291458B2 (ja)	2023-06-15
PH12017501331A1 (en)	2017-12-11
AU2016212116A1 (en)	2017-07-27
RS64308B1 (sr)	2023-07-31
WO2016120258A1 (fr)	2016-08-04
LT3250182T (lt)	2023-07-10
JP2018502928A (ja)	2018-02-01
JP2022176982A (ja)	2022-11-30
CN107205945A (zh)	2017-09-26
IL253626A0 (en)	2017-09-28
US20220331307A1 (en)	2022-10-20
MX2017009681A (es)	2017-10-18
MD3250182T2 (ro)	2023-09-30
IL253626B1 (en)	2024-04-01
ES2948805T3 (es)	2023-09-19
EP3250182A1 (fr)	2017-12-06
MA41411A (fr)	2017-12-05
PH12017501331B1 (en)	2024-02-14
AU2021204135B2 (en)	2023-10-05
KR20170106447A (ko)	2017-09-20
BR112017015784A2 (pt)	2018-03-27
CY1126107T1 (el)	2023-11-15
UA126891C2 (uk)	2023-02-22
IL310920A (en)	2024-04-01
US20180000810A1 (en)	2018-01-04
PE20171319A1 (es)	2017-09-07
JP2021098706A (ja)	2021-07-01
HK1243644A1 (zh)	2018-07-20
SMT202300188T1 (it)	2023-07-20
IL253626B2 (en)	2024-08-01
EP3250182B1 (fr)	2023-04-26
KR102631986B1 (ko)	2024-01-30
DK3250182T3 (da)	2023-06-26

Publication	Publication Date	Title
HRP20230616T1 (hr)	2023-09-29	Disperzivni pripravci
HRP20240231T1 (hr)	2024-04-26	Farmaceutske formulacije inhibitora brutonove tirozin kinaze
WO2014170755A3 (fr)	2015-02-19	Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
HRP20251484T1 (hr)	2026-01-02	Pojačano doziranje tableta rukapariba
JP2015038135A5 (fr)	2015-04-09
JP2006104221A5 (fr)	2008-08-28
HRP20240564T1 (hr)	2024-09-27	Novi farmaceutski sastav
HRP20161340T1 (hr)	2016-12-02	Formulacije darunavira
RU2011152105A (ru)	2013-08-10	Составы таблеток 3-цианохинолина и их применение
JP2018527305A5 (fr)	2019-07-18
WO2018234871A3 (fr)	2019-04-25	Compositions pour administration de médicaments et leurs procédés d'utilisation
SA516370446B1 (ar)	2018-09-13	تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
PH12016500120A1 (en)	2016-04-25	Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX391191B (es)	2025-03-21	Composiciones de liberación extendida de onapristona y métodos.
HK1252549A1 (zh)	2019-05-31	控释tozadenant制剂
RU2018100755A (ru)	2019-07-26	Комбинированный препарат мозаприда и рабепразола
WO2020053658A3 (fr)	2020-07-30	Solutions chimiothérapeutiques non aqueuses de dosage peroral
PH12021552478A1 (en)	2022-06-13	Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile
WO2020089942A3 (fr)	2020-07-23	Composition injectable liquide
HRP20241548T1 (hr)	2025-01-31	Formulacije stimulansa tripulsnog oslobađanja
WO2020086705A3 (fr)	2020-07-30	Compositions pharmaceutiques et procédés de préparation de formulations posologiques solides à la demande
ZA202200331B (en)	2023-11-29	Naltrexone formulation
WO2020032883A3 (fr)	2020-03-26	Effets synergiques d'une nouvelle formulation de kétoprofène comprenant un agent gastro-protecteur
SA521430969B1 (ar)	2023-12-05	تركيبات صيدلانية من توليفة ثابتة الجرعة وفورية الإطلاق، وطرقها، واستخداماتها
HRP20210691T1 (hr)	2021-06-11	Farmaceutski oblici doziranja koji sadrže natrij 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olat